<DOC>
	<DOCNO>NCT03008187</DOCNO>
	<brief_summary>Phase I/II , open-label , multi-center , dose escalation study estimate MTD ( MAD ) SEL24 patient AML . At end Part 1 RD SEL24 select evaluation Part 2 . In Part 2 safety anti-leukemic activity SEL24 assess patient unfit receive intensive chemotherapy .</brief_summary>
	<brief_title>SEL24 Patients With AML</brief_title>
	<detailed_description>This Phase I/II , open-label , multi-center , dose escalation study estimate MTD ( MAD ) SEL24 patient AML . At end Part 1 RD SEL24 select evaluation Part 2 . In Part 2 safety anti-leukemic activity SEL24 assess patient unfit receive intensive chemotherapy . Part 1 commence accelerate dose escalation design first 4 cohort . The study follow 3+3 design Cohort 5 onwards order provide adequate PK profile data . In Part 1 MTD define high dose 1 6 patient experience DLT Cycle 1 . The dose escalation rule follow Part 1 study describe study protocol . The high SEL24 dose level consider well tolerated 6 patient , optimal PK PD characteristic , call RD select evaluation Part 2 . Part 2 enroll patient RD identify Part 1 . The treatment group Part 2 open recruitment base recommendation Investigators , Medical Monitor Sponsor .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>diagnosis AML standard therapeutic option available ( supplement ) anticancer treatment ( include cytotoxic chemotherapy , radiotherapy , hormonal therapy , biologic , immunotherapy investigational drug ) receive within 14 day 5 halflives target therapy ( whichever short ) first dose study drug ( supplement )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>AML</keyword>
</DOC>